Short Interest in Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Expands By 7.6%

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS – Get Rating) was the target of a significant growth in short interest in February. As of February 15th, there was short interest totalling 703,900 shares, a growth of 7.6% from the January 31st total of 654,300 shares. Based on an average daily volume of 910,000 shares, the days-to-cover ratio is currently 0.8 days.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. HC Wainwright lowered their target price on shares of Aridis Pharmaceuticals from $19.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, January 26th. Northland Securities lowered their price objective on shares of Aridis Pharmaceuticals from $5.00 to $2.00 in a research note on Wednesday, November 23rd.

Aridis Pharmaceuticals Stock Performance

ARDS stock opened at $0.52 on Friday. The firm has a market cap of $10.90 million, a price-to-earnings ratio of -0.23 and a beta of 1.07. The firm has a 50-day simple moving average of $0.89 and a two-hundred day simple moving average of $1.07. Aridis Pharmaceuticals has a one year low of $0.48 and a one year high of $2.77.

Hedge Funds Weigh In On Aridis Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. State Street Corp increased its holdings in shares of Aridis Pharmaceuticals by 54.2% during the third quarter. State Street Corp now owns 43,247 shares of the company’s stock valued at $40,000 after acquiring an additional 15,200 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Aridis Pharmaceuticals by 3.3% during the first quarter. Vanguard Group Inc. now owns 524,122 shares of the company’s stock valued at $922,000 after acquiring an additional 16,785 shares in the last quarter. Group One Trading L.P. acquired a new position in shares of Aridis Pharmaceuticals during the first quarter valued at about $48,000. EP Wealth Advisors LLC acquired a new position in shares of Aridis Pharmaceuticals during the third quarter valued at about $47,000. Finally, Armistice Capital LLC acquired a new position in shares of Aridis Pharmaceuticals during the fourth quarter valued at about $2,440,000. Institutional investors and hedge funds own 10.89% of the company’s stock.

Aridis Pharmaceuticals Company Profile

(Get Rating)

Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. The company was founded by Eric J.